Stryker Corporation (SYK) Stock Price, Fundamentals & Analysis

What SYK does

Stryker Corporation (SYK) is a medical technology company that operates in the United States and internationally. It works through two segments: MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment provides surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, and artificial intelligence-assisted virtual care platform technology, along with minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism, traditional brain and open skull based surgical procedures products, and orthobiologic and biosurgery products including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for total joint replacements such as hip, knee, shoulder, ankle, and trauma and extremities surgeries, as well as Mako Shoulder, which expands the smart robotics suite of applications. Stryker Corporation (SYK) is part of the S&P 500.

Key numbers explained

• 273.4 USD is the current share price, the amount you would pay for one share in the market right now.
• The trailing P/E ratio of 28.2 compares the current share price to the last 12 months of earnings per share, showing how much investors are paying for each dollar of recent earnings.
• The forward P/E ratio of 16.3 uses expected future earnings, which can make the stock look less expensive if earnings are expected to grow.
• 9.68 USD is the earnings per share over the trailing 12 months, representing the portion of the company's profit allocated to each outstanding share.
• The dividend yield of 1.28% shows the annual dividend payment as a percentage of the current share price, indicating the cash income relative to the stock's price.
• The ex-dividend date is Sep 30, 2026, meaning you must own the stock before this date to receive the next dividend payment.
• 36% of earnings are paid out as dividends, reflecting the portion of profit returned to shareholders rather than retained for growth or debt reduction.
• 0.77 is the beta, a measure of the stock's volatility compared to the overall market; a beta below 1 suggests it tends to move less than the market.
• The 52-week price range is 267 – 392.55 USD, showing the lowest and highest prices at which the stock has traded over the past year.
• 104.87B USD is the market capitalisation, the total market value of all outstanding shares, placing Stryker Corporation (SYK) among large-cap companies.
• 25.84 mld. USD is the trailing 12-month revenue, and the year-over-year revenue growth of 9.4% shows how quickly the company's top line has expanded.
• 14.4% is the profit margin, indicating the percentage of revenue that becomes net profit.
• The operating margin of 27% shows the percentage of revenue left after covering operating expenses, before interest and taxes.
• 16.5% is the return on equity, measuring how effectively the company generates profit from shareholders' equity.
• The debt-to-equity ratio of 64.4% indicates the proportion of debt used relative to equity to finance the company's assets.
• 4.37 is the price-to-book ratio, comparing the market price to the book value of equity per share.

Recent news

Recent headlines include a comparison of Intuitive Surgical and Stryker to determine which MedTech stock is the better buy now, a discussion of whether Stryker vehicle demand can support General Dynamics' growth, and an article on why you should hold Stryker stock in your portfolio for now. Other stories highlight the surgical devices market size expected to reach USD 27.14 billion by 2030 and a global report on the minimally invasive robotic surgical system market benchmarking Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker, and Zimmer Biomet. A final headline notes that Stryker's foot and ankle push keeps the undervalued narrative in focus.

What to watch

Investors often monitor the medical devices sector for regulatory changes, new product approvals, and competitive dynamics with peers such as Cigna (CI), Bristol Myers Squibb (BMY), Veeva Systems (VEEV), Moderna (MRNA), Edwards Lifesciences (EW), West Pharmaceutical Services (WST), and McKesson Corporation (MCK). Broader factors include healthcare spending trends, reimbursement policy changes, and currency movements, since Stryker Corporation (SYK) operates internationally. Earnings reports, such as the upcoming one on Oct 29, 2026, can drive short-term price moves and shift sentiment.